Select Page

COVID-19 transgenic mouse model


We are ready to answer your questions and provide guidance.


in vitro assays

IITRI offers in vitro testing of potential antivirals against multiple relevant strains of SARS-CoV-2. We source new variants as soon as available for testing and can test the cytotoxicity of your drug as well. Below is a basic study description and design, although IITRI can tailor assays based on your needs.

  • This assay looks at the 50% inhibitory concentration (IC50) of the test article (TA) or serum against SARS-CoV-2.
  • Briefly, cells are plated in a 96 well plate. Serial dilutions (i.e. 1:2, 1:3 or 1:10) of TA or sera are mixed with equal volumes of the virus at a low MOI (i.e. 0.005 TCID50/cell). The virus:TA or sera mixture is added to the cells. The cells are washed and overlaid with media with or without the test article.
  • Other variations are possible to sponsor’s specific requests (TA addition prior to virus inoculation (pretreatment) or after virus inoculation (post treatment).
  • This assay looks at the extent of viral replication measured and expressed as a percentage of virus controls (set to 100% virus replication) and cell controls (set to 0% or background). Virus Controls and Cell Controls are loaded in each plate.
  • 48 hours after virus inoculation, cells are fixed and detected with coronavirus specific monoclonal antibody.

SARS-CoV-2 assay readouts

Contact us today to learn more and discuss how we can partner for infectious disease in vitro assays and animal studies.